In May, the UK National Screening Committee (UKNSC) rejects calls to widen a major prostate cancer screening programme. The decision draws criticism from experts who argue that it was not appropriately justified. Reporting highlights concerns about the composition of the panel that made the ruling, stating that it includes no specialists in the cancer area and no representatives described as Black voices. The article characterizes the dispute as escalating “fury” over a “betrayal,” and says some experts described the decision as amounting to “clinical negligence.” Across the coverage provided, the central points remain the UKNSC’s refusal to expand the screening programme and the allegations that the decision-making process lacked relevant cancer expertise and diversity. The sources do not provide additional details on the evidence considered, any formal reasons published by the UKNSC, or responses from the committee itself beyond the rejection of the expansion request.